Uniquity Bio Announces Statistically Significant and Clinically Meaningful Positive Topline Phase 2 Results for Solrikitug in Eosinophilic E
Solrikitug achieved placebo-corrected histologic remission rates of 69%—76% across all doses tested
Solrikitug achieved placebo-corrected histologic remission rates of 69%—76% across all doses tested